StockIQpro
NASDAQ:ABOS

Acumen Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Acumen Pharmaceuticals, Inc. reported net income of −$121.3M in fiscal 2025. Free cash flow was −$115.6M, and the diluted share count rose 0.9%.Summary generated from Acumen Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−87.7%
Return on equity−96.2%
Debt / equity0.44
Free cash flow−$115.6M
FCF marginn/a
Share count change+0.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−20−45−61−114−124
Net income−101−43−52−102−121
Free cash flow−18−35−43−86−116

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)